Clinical Trial

Monogram Orthopaedics Reports First Quarter 2024 Financial Results

Verification and Validation Testing Expected to be Largely Complete in Q2 2024; 510(k) Submission with FDA Accelerated for Second Half…

1 month ago

Bionic Power Launches $500,000 Agilik Movement Campaign on GoFundMe

The Agilik Movement is a community-building campaign to crowdfund Agilik (TM) smart orthoses for children and teens with knee-extension deficiencies.Vancouver,…

1 month ago

Anumana Appoints Harry S. Palmin as CFO

CAMBRIDGE, Mass.--(BUSINESS WIRE)--#AI--Anumana, a leading AI-driven health technology company and portfolio company of nference, today announced the appointment of Harry…

1 month ago

Anumana Appoints Harry S. Palmin as CFO

CAMBRIDGE, Mass.--(BUSINESS WIRE)--#AI--Anumana, a leading AI-driven health technology company and portfolio company of nference, today announced the appointment of Harry…

1 month ago

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

Lecture to focus on engineering strategies applied to design safe and efficacious bispecific drug candidates, utilizing our proprietary platform technologiesSEATTLE,…

1 month ago

Jaguar Health Reports First Quarter 2024 Financial Results

The combined net Q1 2024 revenue of approximately $2.4 million for prescription and non-prescription products increased approximately 20% versus net…

1 month ago

A Novel Broad-Spectrum Antiviral with Activity Against RSV

Complete Survival of Animals Lethally Infected into Lungs with RSV Achieved Upon NV-387 Oral Treatment SHELTON, CT / ACCESSWIRE /…

1 month ago

aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

Independent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile…

1 month ago

Revolo Biotherapeutics to Present at Upcoming Medical Meetings in May

GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, May 14, 2024 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company…

1 month ago

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to…

1 month ago